First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs NP G2 044 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novita Pharmaceuticals
- 06 Nov 2017 Status changed from not yet recruiting to recruiting.
- 30 Oct 2017 Planned initiation date changed from 15 Oct 2017 to 3 Nov 2017.
- 29 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 15 Oct 2017.